CHEK2 germline pathogenic in mCRPC: included in PROfound Cohort B; olaparib FDA HRR label...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-CHEK2-GERMLINE-PROSTATE |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CIVIC SRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | CHEK2 germline pathogenic |
| Disease | DIS-PROSTATE |
| ESCAT tier | IB |
| Recommended combinations | olaparib monotherapy (post-NHA, FDA HRR label), talazoparib + enzalutamide (HRR-mutated 1L) |
| Evidence summary | CHEK2 germline pathogenic in mCRPC: included in PROfound Cohort B; olaparib FDA HRR label (post-NHA) includes CHEK2 (FDA), though EMA label restricts to BRCA1/2. ESCAT IB (FDA jurisdiction) / OncoKB Level 1. |
Notes
Cascade testing mandatory. CHEK2 carriers face elevated breast cancer risk in relatives.
Used By
No reverse references found in the YAML corpus.